AC
NKTR icon

Armistice Capital’s Nektar Therapeutics NKTR Stock Holding History

Armistice Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.5M Buy
724,000
+146,000
+25% +$10.7M 0.62% 24
2026
Q1 		$41.6M Sell
578,000
-18,000
-3% -$1.02M 0.74% 21
2025
Q4 		$25.2M Buy
596,000
+328,000
+122% +$18.4M 0.3% 53
2025
Q3 		$15.2M Buy
268,000
+144,000
+116% +$4.77M 0.23% 71
2025
Q2 		$3.2M Buy
124,000
+54,933
+80% +$617K 0.06% 117
2025
Q1 		$704K Buy
69,067
+800
+1% +$10.5K 0.01% 174
2024
Q4 		$952K Buy
68,267
+1,600
+2% +$28.2K 0.01% 169
2024
Q3 		$1.3M Buy
66,667
+10,934
+20% +$208K 0.02% 167
2024
Q2 		$1.04M Buy
+55,733
New +$1.17M 0.01% 162

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's NKTR Position: Q2 2026 in Review

Armistice Capital increased its Nektar Therapeutics (NKTR) stake by 25% in Q2 2026, buying an estimated $10.7M and bringing the position to 724,000 shares worth $50.5M. The position accounts for 0.62% of the portfolio, ranked #24.

Armistice Capital first reported a position in NKTR in Q2 2024 and has held it in 9 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Armistice Capital held 724,000 shares of Nektar Therapeutics worth $50.5M as of Q2 2026.
  • Armistice Capital bought 146,000 Nektar Therapeutics shares in Q2 2026, an estimated $10.7M.
  • Nektar Therapeutics made up 0.62% of Armistice Capital's portfolio in Q2 2026, its #24 holding.
  • Armistice Capital first reported a position in Nektar Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.